In Silico Modeling of Angiogenesis at Multiple Scales: From Nanoscale to Organ System

Multiscale Modeling of Particle Interactions: Applications in Biology and Nanotechnology

Volumn , Issue , 2010, Pages 287-320

  Qutub, Amina A ^a   Gabhann, Feilim Mac ^b   Karagiannis, Emmanouil D ^c   Popel, Aleksander S ^b  

^a Rice University   (United States)

^b Johns Hopkins University   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Computational models of angiogenesis key biological questions and multiple biological level follow up; in silico modeling of angiogenesis at multiple scales nanoscale to organ system; Vascular endothelial growth factor (VEGF), collective name for cytokines products of family of five genes, vegfa, vegfb, vegfc, vegfd, and plgf

Indexed keywords

EID: 84886075187     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470579831.ch10     Document Type: Chapter

References (125)

1. Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161(6):1163-1177, 2003.
2. Semenza GL. Hydroxylation of HIF-1 oxygen sensing at the molecular level. Physiology (Bethesda) 19:176-182, 2004.
3. Jiang BH, Semenza GL, Bauer C, Marti HH. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am. J. Physiol. 271 (4 Pt. 1): C1172-C1180, 1996.
4. DewhirstMW, CaoY, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat. Rev. Cancer 8(6):425-437, 2008.
5. Yamazaki Y, Morita T. Molecular and functional diversity of vascular endothelial growth factors. Mol. Divers. 10(4):515-527, 2006.
6. Roskoski R Jr.Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit. Rev. Oncol. Hematol. 62(3):179-213, 2007.
7. Mac Gabhann F, Popel AS. Systems biology of vascular endothelial growth factors. Microcirculation. 15(8):715-738, 2008.
8. Thurston G, Noguera-Troise I, Yancopoulos GD. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat. Rev. Cancer 7(5):327-331, 2007.
9. Amalinei C, Caruntu ID, Balan RA. Biology of metalloproteinases. Rom. J. Morphol. Embryol. 48(4):323-334, 2007.
10. Karagiannis ED, Popel AS. A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells. Proc. Natl. Acad. Sci. USA 105(37):13775-13780, 2008.
11. WhiteCW. Commentary on "Hypoxia, hypoxic signaling, tissue damage, and detection of reactive oxygen species (ROS)." Free Radic. Biol. Med. 40(6):923-927, 2006.
12. Guzy RD, Schumacker PT. Oxygen sensing by mitochondria at complex: III. The paradox of increased reactive oxygen species during hypoxia. Exp. Physiol. 91(5):807-819, 2006.
13. Brune B, Zhou J. The role of nitric oxide (NO) in stability regulation of hypoxia inducible factor-1alpha (HIF-1alpha). Curr. Med. Chem. 10(10):845-855, 2003.
14. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC, Hammerling U, Schumacker PT. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab. 1(6):401-408, 2005.
15. Chandel NS, Budinger GR. The cellular basis for diverse responses to oxygen. Free Radic. Biol. Med. 42(2):165-174, 2007.
16. Kohl R, Zhou J, Brune B. Reactive oxygen species attenuate nitric-oxide-mediated hypoxia-inducible factor-1alpha stabilization. Free Radic. Biol. Med. 40(8): 1430-1442, 2006.
17. Forstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat. Clin. Pract. Cardiovasc. Med. 5(6):338-349, 2008.
18. Kozhukhar AV, Yasinska IM, Sumbayev VV. Nitric oxide inhibits HIF-1alpha protein accumulation under hypoxic conditions: implication of 2-oxoglutarate and iron. Biochimie 88(5):411-418, 2006.
19. Cardillo C, Kilcoyne CM. CannonRO3rd Panza JA. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension 35(6):1237-1241, 2000.
20. Koivunen P, Hirsila M, Remes AM, Hassinen IE, Kivirikko KI, Myllyharju J. Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J. Biol. Chem. 282(7):4524-4532, 2007.
21. Guzy RD, Sharma B, Bell E, Chandel NS, Schumacker PT. Loss of the SdhB, but not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxiainducible factor activation and tumorigenesis. Mol. Cell. Biol. 28(2):718-731, 2008.
22. Qutub A, Popel A. Reactive oxygen species regulate hypoxia-inducible factor HIF1alpha differentially in cancer and ischemia. Mol. Cell. Biol. 28:5106-5119, 2008.
23. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell. Biol. 8(6):464-478, 2007.
24. Siekmann AF, Covassin L, Lawson ND. Modulation of VEGF signalling output by the Notch pathway. Bioessays 30(4):303-313, 2008.
25. HolderfieldMT, Hughes CC. Crosstalk betweenvascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis. Circ. Res. 102(6): 637-652, 2008.
26. Deakin AS. Model for initial vascular patterns in melanoma transplants. Growth 40 (2):191-201, 1976.
27. Balding D, McElwain DL. A mathematical model of tumour-induced capillary growth. J. Theor. Biol. 114(1):53-73, 1985.
28. Chaplain M, Anderson A. Mathematical modelling of tumour-induced angiogenesis: network growth and structure. Cancer Treat. Res. 117:51-75, 2004.
29. Chaplain MA, McDougall SR, Anderson AR. Mathematical modeling of tumor-induced angiogenesis. Annu. Rev. Biomed. Eng. 8:233-257, 2006.
30. Mac Gabhann F, Ji JW, Popel AS. Computational model of vascular endothelial growth factor spatial distribution in muscle and pro-angiogenic cell therapy. PLoS Comput. Biol. 2 (9):e127, 2006.
31. Qutub AA, Popel AS.Acomputational model of intracellular oxygen sensing by hypoxiainducible factor HIF1 alpha. J. Cell Sci. 119(Pt. 16): 3467-3480, 2006.
32. Mac Gabhann F, Popel AS. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 286(1):H153-H164, 2004.
33. Olsen L, Sherratt JA, Maini PK, Arnold F. A mathematical model for the capillary endothelial cell-extracellular matrix interactions in wound-healing angiogenesis. IMA J. Math. Appl. Med. Biol. 14(4):261-281, 1997.
34. Byrne HM, Chaplain MA. Mathematical models for tumour angiogenesis: numerical simulations and nonlinear wave solutions. Bull. Math. Biol. 57(3):461-486, 1995.
35. Grizzi F, Russo C, Colombo P, Franceschini B, Frezza EE, Cobos E, Chiriva-Internati M. Quantitative evaluation and modeling of two-dimensional neovascular network complexity: the surface fractal dimension. BMC Cancer 5:14, 2005.
36. Risser L, Plouraboue F, Steyer A, Cloetens P, Le Duc G, Fonta C. From homogeneous to fractal normal and tumorous microvascular networks in the brain. J. Cereb. Blood Flow Metab. 27(2):293-303, 2007.
37. Bauer AL, Jackson TL, Jiang Y. A Cell-based model exhibiting branching and anastomosis during tumor-induced angiogenesis. Biophys. J. 92(9):3105-3121, 2007.
38. Jabbarzadeh E, Abrams CF. Simulations of chemotaxis and random motility in 2D random porous domains. Bull. Math. Biol. 69(2):747-764, 2007.
39. Anderson AR, Chaplain MA. Continuous and discrete mathematical models of tumorinduced angiogenesis. Bull. Math. Biol. 60(5):857-899, 1998.
40. Peirce SM, Van Gieson EJ, Skalak TC. Multicellular simulation predicts microvascular patterning and in silico tissue assembly. FASEB J. 18(6):731-733, 2004.
41. Stokes CL, Lauffenburger DA. Analysis of the roles of microvessel endothelial cell random motility and chemotaxis in angiogenesis. J. Theor. Biol. 152(3):377-403, 1991.
42. Merks RM, Brodsky SV, Goligorksy MS, Newman SA, Glazier JA. Cell elongation is key to in silico replication of in vitro vasculogenesis and subsequent remodeling. Dev. Biol. 289(1):44-54, 2006.
43. Jabbarzadeh E, Abrams CF. Strategies to enhance capillary formation inside biomaterials: a computational study. Tissue Eng. 13(8):2073-2086, 2007.
44. Tong S, Yuan F. Numerical simulations of angiogenesis in the cornea. Microvasc. Res. 61(1):14-27, 2001.
45. Sun S, Wheeler MF, Obeyesekere M, Patrick CW Jr. A deterministic model of growth factor-induced angiogenesis. Bull. Math. Biol. 67(2):313-337, 2005.
46. Qutub A, Popel AS. Cell elongation, proliferation and migration differentiate endothelial cell phenotypes and determine capillary sprouting. BMC Syst. Biol. 33:13, 2009.
47. Bailey AM, Thorne BC, Peirce SM. Multi-cell agent-based simulation of the microvasculature to study the dynamics of circulating inflammatory cell trafficking. Ann. Biomed. Eng. 35(6):916-936, 2007.
48. Tsoukias NM, Goldman D, Vadapalli A, Pittman RN, Popel AS. A computational model of oxygen delivery by hemoglobin-based oxygen carriers in three-dimensional microvascular networks. J. Theor. Biol. 248(4):657-674, 2007.
49. Pries AR, Secomb TW, Gaehtgens P, Gross JF. Blood flow in microvascular networks. Experiments and simulation. Circ. Res. 67(4):826-834, 1990.
50. Goldman D. Theoretical models of microvascular oxygen transport to tissue. Microcirculation. 15(8):795-811, 2008.
51. Ji JW, Tsoukias NM, Goldman D, Popel AS. A computational model of oxygen transport in skeletal muscle for sprouting and splitting modes of angiogenesis. J. Theor. Biol. 241 (1):94-108, 2006.
52. Shohet RV, Garcia JA. Keeping the engine primed: HIF factors as key regulators of cardiac metabolism and angiogenesis during ischemia. J. Mol. Med. 85(12):1309-1315, 2007.
53. Maynard MA, Qi H, Chung J, Lee EH, Kondo Y, Hara S, Conaway RC, Conaway JW, Ohh M. Multiple splice variants of the human HIF-3 alpha locus are targets of the vonHippel-Lindau E3 ubiquitin ligase complex. J. Biol. Chem. 278(13):11032-11040, 2003.
54. Khanna S, Roy S, Maurer M, Ratan RR, Sen CK. Oxygen-sensitive reset of hypoxiainducible factor transactivation response: prolyl hydroxylases tune the biological normoxic set point. Free Radic. Biol. Med. 40(12):2147-2154, 2006.
55. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, Gleadle JM. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J. Biol. Chem. 279(37):38458-38465, 2004.
56. Powell FL. Functional genomics and the comparative physiology of hypoxia. Annu. Rev. Physiol. 65:203-230, 2003.
57. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helixloop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 92(12):5510-5514, 1995.
58. Pouyssegur J, Mechta-Grigoriou F. Redox regulation of the hypoxia-inducible factor. Biol. Chem. 387(10-11):1337-1346, 2006.
59. Bell EL, Emerling BM, Chandel NS. Mitochondrial regulation of oxygen sensing. Mitochondrion 5(5):322-332, 2005.
60. Pan Y, Mansfield KD, Bertozzi CC, Rudenko V, Chan DA, Giaccia AJ, Simon MC. Multiple factors affecting cellular redox status and energy metabolism modulate hypoxiainducible factor prolyl hydroxylase activity in vivo and in vitro. Mol. Cell. Biol. 27(3): 912-925, 2007.
61. Gottlieb E, Tomlinson IP. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat. Rev. Cancer 5(11):857-866, 2005.
62. Das B, Yeger H, Tsuchida R, Torkin R, Gee MF, Thorner PS, Shibuya M, Malkin D, Baruchel S. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/ extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res. 65(16): 7267-7275, 2005.
63. Ladomery MR, Harper SJ, Bates DO. Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm. Cancer Lett. 249(2):133-142, 2007.
64. Semenza GL. HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev. 19(1-2):59-65, 2000.
65. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 9(4):225-230 (discussion 231), 2006.
66. Staton CA, Kumar I, ReedMW, Brown NJ. Neuropilins in physiological and pathological angiogenesis. J. Pathol. 212(3):237-248, 2007.
67. Soker S, Miao HQ, Nomi M, Takashima S, Klagsbrun M. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J. Cell. Biochem. 85(2):357-368, 2002.
68. Mac Gabhann F, Popel AS. Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: a computational model of human skeletal muscle. Am. J. Physiol. Heart Circ. Physiol. 292(1):H459-H474, 2007.
69. Gitay-Goren H, Soker S, Vlodavsky I, Neufeld G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J. Biol. Chem. 267(9):6093-6098, 1992.
70. Cohen T, Gitay-Goren H, Sharon R, Shibuya M, Halaban R, Levi BZ, Neufeld G. VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J. Biol. Chem. 270(19):11322-11326, 1995.
71. Vander Kooi CW, Jusino MA, Perman B, Neau DB, Bellamy HD, Leahy DJ. Structural basis for ligand and heparin binding to neuropilin B domains. Proc. Natl. Acad. Sci. USA 104(15):6152-6157, 2007.
72. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7(5):575-583, 2001.
73. Hiratsuka S, Maru Y, Okada A, Seiki M, Noda T, Shibuya M. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. 61(3):1207-1213, 2001.
74. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. USA 95(16):9349-9354, 1998.
75. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, De Mol M, Bono F, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat. Med. 9(7):936-943, 2003.
76. Mac Gabhann F, Popel AS. Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1: a computational model. Am. J. Physiol. Heart Circ. Physiol. 288(6):H2851-H2860, 2005.
77. Oh H, Takagi H, Otani A, Koyama S, Kemmochi S, Uemura A, Honda Y. Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis. Proc. Natl. Acad. Sci. USA 99(1):383-388, 2002.
78. Mac Gabhann F, Popel AS. Targeting neuropilin-1 to inhibit VEGF signaling in cancer: comparison of therapeutic approaches. PLoS Comput. Biol. 2(12):e180, 2006.
79. Huang K, Andersson C, Roomans GM, Ito N, Claesson-Welsh L. Signaling properties of VEGF receptor-1 and -2 homo- and heterodimers. Int. J. Biochem. Cell Biol. 33(4): 315-324, 2001.
80. Mac Gabhann F, Popel AS. Dimerization of VEGF receptors and implications for signal transduction: a computational study. Biophys. Chem. 128(2-3):125-139, 2007.
81. Dixelius J, Makinen T,Wirzenius M, Karkkainen MJ,Wernstedt C, Alitalo K, Claesson-Welsh L. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J. Biol. Chem. 278(42):40973-40979, 2003.
82. Ji JW, Mac Gabhann F, Popel AS. Skeletal muscle VEGF gradients in peripheral arterial disease: simulations of rest and exercise. Am. J. Physiol. Heart Circ. Physiol. 293(6): H3740-H3749, 2007.
83. Mac Gabhann F, Ji JW, Popel AS. VEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle. J. Appl. Physiol. 102(2):722-734, 2007.
84. Mac Gabhann F, Ji JW, Popel AS. Multi-scale computational models of pro-angiogenic treatments in peripheral arterial disease. Ann. Biomed. Eng. 35(6):982-994, 2007.
85. Dabrosin C, Chen J,Wang L, Thompson LU. Flaxseed inhibits metastasis and decreases extracellular vascular endothelial growth factor in human breast cancer xenografts. Cancer Lett. 185(1):31-37, 2002.
86. Dabrosin C, Margetts PJ, Gauldie J. Estradiol increases extracellular levels of vascular endothelial growth factor in vivo in murine mammary cancer. Int. J. Cancer 107(4): 535-540, 2003.
87. Hoffner L, Nielsen JJ, Langberg H, Hellsten Y. Exercise but not prostanoids enhance levels of vascular endothelial growth factor and other proliferative agents in human skeletal muscle interstitium. J. Physiol. 550(Pt. 1): 217-225, 2003.
88. Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body?Ameta-analysis of VEGF distribution in cancer. Br. J. Cancer 97(7):978-985, 2007.
89. Wu FTH, Stefanini MO, Mac Gabhann F, Popel AS.A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap. PLoS ONE, 4(4):e5108, 2009.
90. Stefanini MO, Wu FT, Mac Gabhann F, Popel AS. A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst. Biol. 2:77, 2008.
91. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267(36):26031-26037, 1992.
92. Takeda N, Maemura K, Imai Y, Harada T, Kawanami D, Nojiri T, Manabe I, Nagai R. Endothelial PAS domain protein 1 gene promotes angiogenesis through the transactivation of both vascular endothelial growth factor and its receptor. Flt-1. Circ. Res. 95(2):146-153,2004.
93. Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, Ferrara N. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol.Chem. 271(13):7788-7795, 1996.
94. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell Biol. 169(4):681-691, 2005.
95. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J. Biol.Chem. 271(17):10079-10086, 1996.
96. Cauwe B,Van den Steen PE,Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates Processed by matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 42(3):113-185, 2007.
97. Ichikawa Y, Ishikawa T, Momiyama N, Kamiyama M, Sakurada H, Matsuyama R, Hasegawa S, Chishima T, Hamaguchi Y, Fujii S, et al. Matrilysin (MMP-7) degrades VEcadherin and accelerates accumulation of beta-catenin in the nucleus of human umbilical vein endothelial cells. Oncol. Rep. 15(2):311-315, 2006.
98. Ratnikov BI, Rozanov DV, Postnova TI, Baciu PG, Zhang H, DiScipio RG, Chestukhina GG, Smith JW, Deryugina EI, Strongin AY. An alternative Processing of integrin alpha(v) subunit in tumor cells by membrane type-1 matrix metalloproteinase. J. Biol.Chem. 277(9):7377-7385, 2002.
99. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92(8):827-839, 2003.
100. Haas TL, Milkiewicz M, Davis SJ, Zhou AL, Egginton S, Brown MD, Madri JA, Hudlicka O. Matrix metalloproteinase activity is required for activity-induced angiogenesis in rat skeletal muscle. Am. J. Physiol. Heart Circ. Physiol. 279(4):H1540-H1547, 2000.
101. Chun TH, Sabeh F, Ota I, Murphy H, McDonagh KT, Holmbeck K, Birkedal-Hansen H, Allen ED, Weiss SJ. MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J. Cell Biol. 167(4):757-767, 2004.
102. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat. Rev. Mol. Cell Biol. 3(3):207-214, 2002.
103. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol. 37(6):375-536, 2002.
104. Woessner JF Jr. MMPs and TIMPs: an historical perspective. Mol. Biotechnol. 22(1): 33-49, 2002.
105. Butler GS, Butler MJ, Atkinson SJ,Will H, Tamura T, Schade vanWestrum S, Crabbe T, Clements J, d'Ortho MP, Murphy G. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A: a kinetic study. J. Biol. Chem. 273(2):871-880, 1998.
106. Karagiannis ED, Popel AS. A theoretical model of type I collagen proteolysis by matrix metalloproteinase (MMP) 2 and membrane type 1MMPin the presence of tissue inhibitor of metalloproteinase 2. J. Biol. Chem. 279(37):39105-39114, 2004.
107. Karagiannis ED, Popel AS. Distinct modes of collagen type I proteolysis by matrix metalloproteinase (MMP) 2 and membrane type I MMP during the migration of a tip endothelial cell: insights from a computational model. J. Theor. Biol. 238(1):124-145, 2006.
108. Sottile J. Regulation of angiogenesis by extracellular matrix. Biochim. Biophys. Acta Rev. Cancer 1654(1):13-22, 2004.
109. Murphy G, Gavrilovic J. Proteolysis and cell migration: creating a path? Curr. Opin. Cell Biol. 11(5):614-621, 1999.
110. Horino K, Kindezelskii AL, Elner VM, Hughes BA, Petty HR. Tumor cell invasion of model 3-dimensional matrices: demonstration of migratory pathways, collagen disruption, and intercellular cooperation. FASEB J. 15(6):932-939, 2001.
111. Koike T, Vernon RB, Hamner MA, Sadoun E, Reed MJ. MT1-MMP, but not secreted MMPs, influences the migration of human microvascular endothelial cells in 3-dimensional collagen gels. J. Cell. Biochem. 86(4):748-758, 2002.
112. Galvez BG, Matias-Roman S, Albar JP, Sanchez-Madrid F, Arroyo AG. Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J. Biol. Chem. 276 (40):37491-37500, 2001.
113. Hotary K, Allen E, Punturieri A, Yana I, Weiss SJ. Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J. Cell Biol. 149(6):1309-1323, 2000.
114. Koike T, Vernon RB, Hamner MA, Sadoun E, Reed MJ. MT1-MMP, but not secreted MMPs, influences the migration of human microvascular endothelial cells in 3-dimensional collagen gels. J. Cell. Biochem. 86(4):748-758, 2002.
115. Vempati P, Karagiannis ED, Popel AS. A biochemical model of the matrix metalloproteinase 9 activation and inhibition. J. Biol. Chem. 282(52):37585-37596, 2007.
116. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol.Cell 4(12):1317-1326, 1993.
117. Rundhaug JE. Matrix metalloproteinases and angiogenesis. J. Cell. Mol. Med. 9(2): 267-285, 2005.
118. Qutub AA, Liu G, Vempati P, Popel AS. Integration of angiogenesis modules at multiple scales: from molecular to tissue. Proceedings of the Pacific Symposium on Biocomputation, 316-327, 2009.
119. Gale NW, Dominguez MG, Noguera I, Pan L, Hughes V, Valenzuela DM, Murphy AJ, Adams NC, Lin HC, Holash J, et al. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc. Natl. Acad. Sci. USA 101(45):15949-15954, 2004.
120. Krebs LT, Shutter JR, Tanigaki K, Honjo T, Stark KL, Gridley T. Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Genes Dev. 18(20):2469-2473, 2004.
121. Duarte A, Hirashima M, Benedito R, Trindade A, Diniz P, Bekman E, Costa L, Henrique D, Rossant J. Dosage-sensitive requirement for mouse Dll4 in artery development. Genes Dev. 18(20):2474-2478, 2004.
122. Lobov IB, Renard RA, Papadopoulos N, Gale NW, Thurston G, Yancopoulos GD, Wiegand SJ. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc. Natl. Acad. Sci. USA 104(9):3219-3224, 2007.
123. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444(7122):1032-1037, 2006.
124. Sainson RC, Aoto J, Nakatsu MN, Holderfield M, Conn E, Koller E, Hughes CC. Cellautonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulogenesis. FASEB J. 19(8):1027-1029, 2005.
125. Hellstrom M, Phng LK, Hofmann JJ,Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445(7129):776-780, 2007.